5 ways healthcare hopes to improve prior authorization

Prior authorization is often listed as one of the biggest hassles for many healthcare facilities, with plenty of calls for collaboration between major associations to streamline the onerous process. Those efforts have now led to a consensus statement from six groups on their shared goals for preapproving patients’ medical treatments.

The American Hospital Association, America’s Health Insurance Plans, American Medical Association, American Pharmacists Association (APhA), Blue Cross Blue Shield Association and Medical Group Management Association recommended focusing on five areas of improvement:

  1. Selective application of prior authorization
  2. Program review and volume adjustment
  3. Transparency and communication
  4. Continuity of patient care
  5. Automation to improve transparency and efficiency

“Meeting health plan proprietary authorization requirements consume significant time for both clinical and administrative personnel, diverting staff away from providing direct patient care, and costing practices countless dollars to administer,” Anders Gilberg, MGMA’s senior vice president of government affairs, said in a statement. “Most importantly, the prior authorization process can result in delayed or denied patient care.”

Read more at Cardiovascular Business:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.